Intended use:

The RIDASCREEN® VDZ Monitoring is an enzyme linked immunosorbent assay intended for the quantitative determination of vedolizumab (VDZ, Entyvio®, anti- integrin α4β7) in human serum and plasma.

Product information

Vedolizumab (VDZ, Entyvio®) is approved for the treatment of patients with moderate to severe Crohn’s disease and ulcerative colitis in whom conventional therapy or anti-TNFα therapies were ineffective or not tolerated. It is a gut-specific, humanized monoclonal antibody targeting the α4β7-integrin protein, which is involved in the migration of lymphocytes to the gut. Similar as to anti-TNFα drugs, measurement of vedolizumab drug concentrations supports a personalized dosing strategy in patients treated with vedolizumab.

The RIDASCREEN® VDZ Monitoring and our other TDM assays are vital to personalize treatment of patients with Crohn’s disease and ulcerative colitis and better achieve therapeutic targets.

Key features:

  • CE-marked version of the ELISA tests of KU Leuven
  • Highly specific antibodies
  • Ready to use reagents
  • Validated for use on automated ELISA systems, e.g. the Dynex DSX®
Art. No. G09045
Test format Microtiter plate with 96 wells (12 strips with 8 removable wells each)
Incubation time 1 h 40 min
Spanish (English) (German) (French) (Italian) (Spanish)
Similar Products
RIDASCREEN® Helicobacter
RIDASCREEN® Helicobacter
For in vitro diagnostic use. RIDASCREEN® Helicobacter is an enzyme immunoassay (EIA) for the qualitative detection of Helicobacter pylori-specific ...
RIDA®QUICK ADM Monitoring Control Set
RIDA®QUICK ADM Monitoring C...
For in vitro diagnostic use. The RIDA®QUICK ADM Monitoring Control Set is intended for the use with the corresponding, batch specific kit RIDA®QUIC...
For in-vitro diagnostics. This test is a lateral flow immunochromatographic assay for the quantitative detection of adalimumab (ADM, Humira®) in hu...

Start typing and press Enter to search